Cloacogenic Carcinoma of the Rectum

PULL‐THROUGH OPERATIONS FOR CARCINOMA OF THE RECTUM

The Medical Journal of Australia ◽

10.5694/j.1326-5377.1962.tb20944.x ◽

1962 ◽

Vol 2 (23) ◽

pp. 907-909 ◽

Cited By ~ 11

Author(s):

E. S. R. Hughes ◽

A. M. Cuthbertson ◽

A. B. G. Carden

Keyword(s):

Carcinoma Of The Rectum ◽

Pull Through

Download Full-text

Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy

Oxford Medical Case Reports ◽

10.1093/omcr/omaa097 ◽

2020 ◽

Vol 2020 (11) ◽

Author(s):

Nobumasa Tamura ◽

Yoshitaka Honma ◽

Shigeki Sekine ◽

Shunsuke Tsukamoto ◽

Hidekazu Hirano ◽

...

Keyword(s):

Progression Free Survival ◽

First Line ◽

Epithelial Tumor ◽

Carcinoma Of The Rectum ◽

Free Survival ◽

Lymph Nodes Dissection ◽

Multiple Liver Metastases ◽

Submucosal Lesion ◽

Line Chemotherapy ◽

Endocrine Features

ABSTRACT Amphicrine carcinoma (AmC) is a unique epithelial tumor displaying exocrine and endocrine features in the same cell. It shows an adenocarcinoma-like cellular form and has endocrine granules. There are few reports describing chemotherapy for AmC. Here, we describe a case with metastatic AmC from the rectum that was treated with FOLFOXIRI chemotherapy. A 64-year-old man was diagnosed with a submucosal lesion on the scar produced after an endoscopic mucosal resection, which had been performed for adenocarcinoma of the rectum 2 years before. The endoscopic submucosal dissection revealed AmC. The abdominoperineal resection including lymph nodes dissection was performed. Thereafter, computed tomography showed multiple liver metastases, and FOLFOXIRI was administered. The best overall response was partial response, and progression-free survival was 8.7 months. After 16.0 months since first-line chemotherapy the patient died. We can therefore conclude that FOLFOXIRI may be effective for AmC of the rectum.

Download Full-text